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Abstract
There has been great interest in genetic risk prediction using risk scores in recent years,
however, the utility of scores developed in European populations and later applied to non-
European populations has not been successful. The goal of this study was to create a meth-
ylation risk score (MRS) for metabolic syndrome (MetS), demonstrating the utility of MRS
across race groups using cross-sectional data from the Hypertension Genetic Epidemiology
Network (HyperGEN, N = 614 African Americans (AA)) and the Genetics of Lipid Lowering
Drugs and Diet Network (GOLDN, N = 995 European Americans (EA)). To demonstrate
this, we first selected cytosine-guanine dinucleotides (CpG) sites measured on Illumina
Methyl450 arrays previously reported to be significantly associated with MetS and/or com-
ponent conditions in more than one race/ethnic group (CPT1A cg00574958, PHOSPHO1
cg02650017, ABCG1 cg06500161, SREBF1 cg11024682, SOCS3 cg18181703, TXNIP
cg19693031). Second, we calculated the parameter estimates for the 6 CpGs in the Hyper-
GEN data (AA) and used the beta estimates as weights to construct a MRS in HyperGEN
(AA), which was validated in GOLDN (EA). We performed association analyses using logis-
tic mixed models to test the association between the MRS and MetS, adjusting for covari-
ates. Results showed the MRS was significantly associated with MetS in both populations.
In summary, a MRS for MetS was a strong predictor for the condition across two race
groups, suggesting MRS may be useful to examine metabolic disease risk or related compli-
cations across race/ethnic groups.
Introduction
Genome wide association studies (GWAS) have examined the cumulative effect of novel, sin-
gle variants on both quantitative trait variance and disease status, by summing up independent
risk alleles at each locus weighted by effect size, otherwise known as a genetic risk score (GRS)
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[1]. While once limited by small sample sizes, GRSs have since benefitted from the growth and
development of large-disease based consortia, along with improved methodology which allow
for the aggregation of thousands to millions of genetic variants (i.e. polygenic risk scores,
PRS), which better inform risk prediction [2]. A major limitation of GRS–including PRS—is
that they have been developed and optimized for European-ancestry populations, thus limiting
their utility and generalizability in non-European ancestry populations [3, 4]. Overall, GWAS
results and GRS have been difficult to replicate across race groups for complex disease. This is
in contrast to data on DNA methylation which has demonstrated more successful cross-race
replication [3, 5, 6]. Given these observations we aimed to apply statistical approaches com-
mon to GRS and PRS to epigenome-wide association (EWAS) data to evaluate if methylation
risk score (MRS) may further enhance accuracy for prediction of metabolic syndrome, a clus-
ter of conditions that can increase risk for cardiometabolic diseases. We hypothesized that
leveraging existing EWAS data and previously reported associations between cytosine-phos-
phate-guanine (CpG) sites and metabolic syndrome may help identify persons with elevated
risk for MetS.
There is a rich body of literature demonstrating independent associations between DNA
methylation loci and MetS and/or conditions related to MetS such as obesity [7–9], insulin
resistance (9), and type 2 diabetes [10–12]. In this study, we leverage previously reported CpGs
that have been significantly associated with MetS and/or conditions comprising MetS in more
than one race/ethnic group: waist circumference [5], triglycerides [13], fasting blood glucose
[11], systolic and diastolic blood pressure [14], and HDL cholesterol [15, 16], to construct the
MRS. Independent CpGs included were cg00574958 from carnitine palmitoyl transferase 1A
(CPT1A), cg02650017 from Phosphoethanolamine/Phosphocholine Phosphatase 1 (PHOS-
PHO1), cg06500161 from ATP Binding Cassette Subfamily G Member 1 (ABCG1),
cg11024682 from Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1),
cg18181703 from Suppressor Of Cytokine Signaling 3 (SOCS3), and cg19693031 from Thiore-
doxin Interacting Protein (TXNIP). Bolstering to the validity of our CpG selection each gene
has strong biological plausibility for association with MetS including roles in fatty acid metab-
olism (CPT1A) [17], lipid homeostasis and metabolism (SREBF1 [18], ABCG1) [19], skeletal
endocrine regulation of metabolism (PHOSPHO1) [20], cytokine signaling (SOCS3) [21] and
oxidative stress (TXNIP) [22].
Like existing GWAS data existing methylation data can be used to calculate risk scores that
could become useful for diagnosis and/or prevention. Building on GRS methods we used a
weighted sum approach to create a MRS among African Americans from the Hypertension
Genetic Epidemiology Network (HyperGEN), Wevalidated the score in European Americans
from Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). We further examined
the score’s association with the individual MetS components and stratified by sex.
Methods
Discovery and validation study populations
Data for the discovery phase of this study was obtained from the HyperGEN study. HyperGEN
is a cross-sectional study including over 1900 African-Americans from families, which
included at least two siblings with hypertension onset before age 60 [23]. The study purpose
was to examine possible interactions between genetic and non-genetic determinants of hyper-
tension. In 2015, an ancillary epigenetic study was conducted on stored HyperGEN samples in
the upper and lower tertial of echocardiography measured left ventricular mass [24]. After
excluding those missing relevant phenotype data as previously described [25] a total 614 par-
ticipants were included in the analysis. Participants in the HyperGEN and GOLDN studies
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provided written and oral informed consent to participate in these studies and both studies
were approved by the Institutional Review Board at the University of Alabama at Birmingham.
Validation was conducted in GOLDN study [26]. European ancestry families in GOLDN
were recruited from the Family Heart Study at two centers, Minneapolis, MN and Salt Lake
City, UT to participate in a diet and/or drug intervention. In each case, only families with at
least two siblings were recruited and only participants who did not take lipid-lowering agents
(pharmaceuticals or nutraceuticals) for at least 4 weeks prior to the initial visit were included.
For the present study, 994 GOLDN participants had available methylation data for a validation
study of the HyperGEN MRS. Sample characteristics as well as clinical and lifestyle factors
were considered in HyperGEN and GOLDN, including blood pressure, antihypertensive and
lipid lowering medications, fasting blood glucose, triglycerides, HDL cholesterol, height,
weight, and waist circumference have been described [7–9]. We used the published joint har-
monized criteria to define MetS in HyperGEN in both studies [27].
DNA methylation and data processing
HyperGEN. The Illumina HumanMethylation450 array was used to analyze DNA
extracted from buffy coat obtained from whole blood samples at> 480,000 cytosine-phos-
phate-guanine (CpG) sites. Briefly, 500 ng of buffy coat DNA was hybridized to the Methyl450
array after bisulfite conversion with EZ DNA kits (Zymo Research, Irvine, CA) prior to stan-
dard Illumina amplification, hybridization, and imaging steps. The resulting intensity files
were analyzed with Illumina’s GenomeStudio, which generated beta (β) scores (i.e., the pro-
portion of total signal from the methylation-specific probe or color channel) and “detection p
values” (probability that the total intensity for a given probe falls within the background signal
intensity). Quality control (QC) measures were conducted by removing samples having more
than 1% of CpG sites with a detection p value > 0.05, removing CpG sites having more than
5% of samples with a detection p value> 0.01, and individual CpG sites with detection p value
> 0.01 set as missing. After these QC filters, 484,366 CpG sites were eligible for analysis. We
normalized the β scores using the Subset-quantile Within Array Normalization (SWAN)
method in minifi package to correct for differences between batches and the type I and type II
assay designs within a single 450K array [28]. Cell count proportions (CD8 T lymphocytes,
CD4 T lymphocytes, natural killer cells, B cells, and monocytes) were created using the algo-
rithm developed by Houseman, which predicts underlying cellular composition of each sample
from DNA methylation patterns [29].
GOLDN. CD4+ T-cells were isolated from frozen buffy coat samples stored from whole
blood peripheral blood collected at the baseline visit (prior to intervention). DNA was
extracted using DNeasy kits (Qiagen, Venlo, Netherlands). 500ng of each DNA sample was
treated with sodium bisulfite (Zymo Research, Irvine, CA). Normalization was performed on
random subsets of 10,000 CpGs per run, with each array of 12 samples used as a "batch."
Probes from the Infinium I and II chemistries were separately normalized and β scores for
Infinium II probes were then adjusted using the equation derived from fitting a second order
polynomial to the observed methylation values across all pairs of probes located<50bp apart
(within-chemistry correlations >0.99), where one probe was Infinium I and one was Infinium
II. The filtered β scores were normalized using the ComBat R-package.
CgG candidate selection. The following 6 CpGs were used to construct our MRS:
cg00574958 within CPT1A, cg02650017 within PHOSPHO1, cg06500161 within ABCG1,
cg11024682 within SREBF1, cg18181703 within SOCS3, and cg19693031 within TXNIP. To
select the CpGs for the score, first we started with results from GOLDN (European Ancestry)
and HyperGEN (African Ancestry) EWAS, which found replicated association of CPT1A and
PLOS ONE A 6-CpG validated methylation risk score model for metabolic syndrome
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ABCG1 with MetS, respectively. In those studies, no other genes were statistically significant in
the discovery cohort and replicated externally. However, prior work in GOLDN and Hyper-
GEN showed robust associations between cg00574958 (CPT1A) and lipids/BMI and between
cg06500161 (ABCG1) and fasting glucose/insulin. To expand our score beyond GOLDN and
HyperGEN findings, we included the CpG sites in PHOSPHO1, SREBF1, TXNIP and SOCS2
which—together with ABCG1 –comprised the type 2 diabetes methylation risk score published
by Chambers, et al [10]. Those additional CpGs were selected due to their association with
multiple MetS component traits across at least two race groups in multiple cohorts. Helping to
further validate our gene selection a more recent EWAS of MetS reported replicated associa-
tion for three of our 6 CpGs sites in TXNIP, ABCG1, and SREBF1 [30]. Additional references
for these CpGs and their biological relevance are included in Table 1.
Methylation risk score model building. A logistic mixed model was used to test the asso-
ciation between methylation at each candidate CpG site and MetS in HyperGEN. We adjusted
for age, sex, study site, and estimated blood cell counts as fixed effects, and family structure as
a random effect. Parallel models were implemented in GOLDN except methylation principal
components replaced the estimated blood cell counts to adjust for cell type impurity (GOLDN
was of a single cell type). To calculate the MRS, Z-values from the candidate CpG HyperGEN
models described above (shown in Table 2) were utilized as weights and multiplied by the
CpG-values and the product was summed to generate a risk score for each sample ((Z1
� cpg1
beta score) + (Z2
� cpg2 beta score)+ . . . (Z6
� cpg6 beta score)). The mean and standard deviation of
the score in HyperGEN was calculated. Each participants MRS was then standardized by sub-
tracting the mean and dividing by the standard deviation. We used a parallel approach to cal-
culate the standardized MRS in GOLDN by using GOLDN CpG values weighted by the
HyperGEN Z-values.
Methylation risk score model performance testing. We compared both HyperGEN and
GOLDN characteristics between individuals with (MetS+) and without (MetS-) metabolic syn-
drome. Significance of these characteristics were calculated using a simple t test for continuous
traits and a chi-square test for binary traits. We then tested the association between the
Table 1. CPG selection literature review.
Gene Trait(s) Function Race/Ethnicity groups Direction of
Association (MetS
and/or Diabetes)
ATP Binding Cassette sub-
family G member 1
(ABCG1)
Lipids [10, 12, 16, 30, 47, 48],
diabetes-related [10–12], adiposity









Lipids [16, 47, 48, 50], Blood
pressure [14], adiposity [5, 51],
metabolic syndrome [52],
adiponectin [53]
Fatty acid oxidation Europeans [14, 47, 48, 50–52,














Lipids [12], diabetes-related, [10],
adiposity [12, 55], metabolic
syndrome [56]
Regulates cytokine or hormone
signaling, inhibits STAT3 activation






Lipids, [16, 47, 48], diabetes-related,
[10, 30], adiposity [57]





Lipids [48], diabetes-related, [10, 30] Required for the maturation of
natural killer cells, suppresses tumor
growth
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standardized MRS and MetS (outcome) using a logistic mixed model in HyperGEN adjusting
for age, sex, study site, 4 ancestry principal components, estimated blood cell counts as fixed
effects, and family id as a random effect. We conducted a 100,000-permutation test to evaluate
statistical significance of the relationship between the MRS and MetS in HyperGEN. In
GOLDN we used a logistic mixed model to test the association between the GOLDN standard-
ized MRS and MetS adjusting for age, sex, study site, and methylation PCs as fixed effects, and
family id as a random effect. Secondary analysis of the score with individual MetS components
and by sex were carried out in each study.
Results
Study population characteristics
Demographic characteristics of the HyperGEN (N = 614) and GOLDN (N = 995) populations
—with and without MetS—are presented in Table 2. The majority of participants were female
in both HyperGEN (66.61%) and GOLDN (52.26%), with an overall mean age of 49 and 50
years, respectively. Participants with MetS (MetS+) were older compared to those without
(MetS-) (HyperGEN: 52 ± 10 years and 46 ±11 years, and GOLDN: 56 ±13 and 44 ±16, respec-
tively) and more likely to be male in GOLDN and female in HyperGEN, respectively. In
HyperGEN 56.2% of participants with MetS had 3 of the 5 (i.e. WC, BP, TG, HDL and FG)
possible components (N = 149) and fewer had 4 (N = 77, 28.7%) and 5 (N = 42, 15.7%) compo-
nents, while in GOLDN, 47.5% of individuals met 3 out of 5 components (N = 187), 35.1% had
4 of 5 (N = 138) and 17.3% had 5 of 5 (N = 68) components.
Table 3 shows the 6 candidate CpG association results for MetS in HyperGEN and
GOLDN. With the exception of cg02650017 in PHOSPHO1, which was not significant in
either study, the direction of association of the CpG with MetS was consistent between
GOLDN and HyperGEN with at least marginal significance. Only cg18181703 in SOC3S was
not associated with MetS in GOLDN. Both CPT1A cg00574958 and ABCG1 cg06500161 were
strongly associated with MetS in both studies (P<0.0001). Finally, the direction of association
for CPT1A, ABCG1, SOCS3, TXNIP and SREBF1 was consistent with that reported in the liter-
ature for MetS and/or diabetes (Table 1).
Risk score discovery and validation
Fig 1 shows the normal distribution of the standardized MRS in the GOLDN cohort. Results
from association analyses of the MRS with MetS after adjustment for covariates in HyperGEN
and GOLDN are presented in Table 4. In HyperGEN, the MRS was significantly associated
with MetS (permutation test p<0.0001), with each standard deviation (SD) increase in the
score associated with 2.25 higher odds of having MetS (OR = 2.25; 95% CI: 1.79–2.86). The
MetS and MRS relationship was also significant in GOLDN where similarly, a 1 SD increase in
the score was associated with 2.45 higher odds of having MetS (OR = 2.45; 95% CI: 2.02–3.00).
Results for the individual components show the score was most strongly associated with waist
circumference, triglycerides and glucose in each study (Table 4). Results stratified by sex show
showed the score was generally consistent by gender though slightly more significant in
females. We also tested the interaction between MetS and sex, however that interaction was
not significant in either HyperGEN or GOLDN.
Discussion
Signatures of DNA methylation associated with cardiometabolic diseases have not been widely
tested for their utility in generating genomic risk scores. With better replication results across
PLOS ONE A 6-CpG validated methylation risk score model for metabolic syndrome
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external groups and even by race these CpGs may prove useful for evaluating disease risk.
Here, we introduce a six-CpG methylation risk score estimate for MetS that was consistent in
two independent populations (HyperGEN and GOLDN). Overall, the successful performance
of this MRS in two different racial populations, provides promise for future exploration of
MRSs for complex disease prediction.
A substantial number of studies support the role of DNA methylation in MetS and its com-
ponents. However, unlike studies of single nucleotide polymorphisms (SNPs) that have exten-
sively considered the utility of GRS and PRS (noting many limitations, especially with respect
to race), relatively few publications have included MRS [3, 31]. For instance, Hamilton et al,
reported a positive association between an epigenetic BMI risk score and higher BMI (R2 =
0.1) in the Lothian Birth Cohort [32]. MRS for arterial stiffness measurements have been
Table 2. Baseline characteristics of HyperGEN and GOLDN study participants.
HyperGEN N = 614 GOLDN N = 995
MetS - MetS + P� MetS - MetS+ P�
n = 346 n = 268 n = 602 n = 393
Sex
Female (%) 61.85 72.76 0.014 56.81 45.29 <0.001
Age 45.67 ±11.02 51.66 ±10.35 <0.0001 44.01 ±16.03 56.16 ±13.88 <0.0001
High WC
WC (cm) 96.56 ±16.91 112.40 ±16.55 <0.0001 89.35 ±13.35 107.57 ±13.89 <0.0001
Elevated BP
SBP (mmHg) 127.59 ±23.72 136.03 ±22.83 <0.0001 110.65 ±14.17 123.21 ±17.54 <0.001
DBP (mmHg) 75.48 ±13.25 75.25±11.84 <0.0001 66.09 ±8.46 71.39 ±9.78 <0.0001
Elevated Triglycerides
77.00 ±35.82 125.50 ±134.61 <0.0001 91.44 ±61.22 176.92 ±107.2 <0.0001
Reduced
HDL
Cholesterol 58.75 ±15.52 46.93 ±12.45 <0.0001 49.54 ±13.22 39.22 ±11.44 <0.0001
Elevated FG
FG 89.00 ±31.22 110.00 ±69.88 <0.0001 94.0 ±10.34 105.0 ±18.91 <0.0001
MetS MRS -0.38 ±0.95 0.31 ±0.94 <0.0001 -0.30 ±0.93 0.47 ±0.92 <0.0001
Metabolic Components��
0 57 0 174 0
1 115 0 214 0
2 169 0 214 0
3 0 149 0 187
4 0 77 0 138
5 0 42 0 68
Abbreviations: MetS = Metabolic Syndrome, WC = Waist Circumference, BP = Blood Pressure, SBP = systolic blood pressure, DBP = diastolic blood pressure,
HDL = high-density lipoprotein, FG = Fasting glucose.
Thresholds: (1) Waist circumference (� 88 cm for women and� 102 cm for men), (2) elevated triglycerides (� 150 mg/dL) or on treatment for dyslipidemia (statin
and/or fibric acid derivative), (3) reduced high-density lipoprotein (HDL) cholesterol (< 40 mg/dL in men and < 50 mg/dL in women) or on treatment for dyslipidemia
(statin and/or fibric acid derivative), (4) elevated blood pressure (systolic� 130 and/or diastolic� 85 mmHg) or antihypertensive drug treatment in a patient with a
history of hypertension), and (5) elevated fasting glucose (� 100 mg/dL) or drug treatment for elevated glucose.
�Significance determined using chi-square test for categorical, t-test for continuous, or kruskal test for non-parametric continuous variables with 95% CI.
��Metabolic components are high waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose.
���There are 5 individuals with NA for 1–2 components making the total 341 rather than 346 for MetS- in HyperGEN.
https://doi.org/10.1371/journal.pone.0259836.t002
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reported using data from the REGICOR and Framingham studies. In that study, two different
MRS (based on alternate analytical approaches) were directly associated with arterial disten-
sibility coefficient and inversely with pulse wave velocity [33]. Braun and others constructed a
MRS in the Rotterdam study for HDL and triglycerides, finding that HDL-C levels decreased
as quartiles of MRS increase, while triglyceride levels increased from the first quartile to the
second quartile but remained similar for the third quartile and the fourth quartile of the MRS
[34]. In another EWAS for BMI, a MRS constructed from the findings predicted future
Table 3. Single CPG and MetS association results for GOLDN and HyperGEN.
Genes CpG site Estimate SE Z-score P-value
HyperGEN� Participants (N = 614) CPT1A cg00574958 -0.495 0.113 -4.396 1.10E-05
PHOSPHO1 cg02650017 -0.133 0.101 -1.312 0.189
ABCG1 cg06500161 0.550 0.113 4.865 1.15E-06
SREBF1 cg11024682 0.570 0.119 4.777 1.78E-06
SOCS3 cg18181703 -0.204 0.095 -2.153 0.031
TXNIP cg19693031 -0.402 0.102 -3.939 8.18E-05
GOLDN�� Participants (N = 994) CPT1A cg00574958 -0.852 0.113 -7.539 4.72E-14
PHOSPHO1 cg02650017 0.062 0.097 0.632 0.527
ABCG1 cg06500161 0.394 0.099 3.966 7.31E-05
SREBF1 cg11024682 0.270 0.119 2.269 0.023
SOCS3 cg18181703 -0.059 0.095 -0.623 0.533
TXNIP cg19693031 -0.267 0.092 -2.915 0.004
�HyperGEN model adjusted for age, sex, study site, 4 ancestry principle components, estimated blood cell counts (CD8T cells, CD4T cells, Natural Killer cells, B-cells,
Monocyte cells) as fixed effects, and family id as a random effect.
��GOLDN model adjusted for age, sex, study site, 4 methylation principle components, and family id as a random effect.
https://doi.org/10.1371/journal.pone.0259836.t003
Fig 1. GOLDN MetS-score distribution, N = 994.
https://doi.org/10.1371/journal.pone.0259836.g001
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development of type 2 diabetes [35]. Finally, in the study of type 2 diabetes (~2000 Asian Indi-
ans and ~1000 Europeans) the Chambers et al score was associated with developing type 2 dia-
betes (RR of type 2 diabetes incidence 1�41 per 1 SD change in methylation score;
p = 1�3 × 10−26) [10]. Along with our study these findings suggest promise in the use of methyl-
ation scores for metabolic disease risk prediction.
Generation of genomic risk scores is an evolving field. Some approaches focus on biological
candidates and/or statistically significant markers for inclusion, while others include hundreds
of thousands or more markers capturing small polygenic effects [22, 36]. We selected a limited
number of CpGs that had strong statistical association with relevant traits and replication in at
least two race groups. Each of the CpGs was highly biologically relevant being associated with
fatty acid metabolism (CPT1A), reverse cholesterol transport particularly HDL (ABCG1), oxi-
dative stress mediation (TXNIP), phosphatase activity involving glycerophospholipid biosyn-
thesis (PHOSPHO1), inhibition of cytokine signal transduction by binding to tyrosine kinase
inhibitors including insulin and leptin receptors (SOCS3), and sterol biosynthesis (SREBF1)
(Table 1). Other studies noted above took a similar approach to construct methylation risk
scores using statistically significant findings (20, 23) or a combination of statistical significance
and the literature to select a short list of CpGs (21).
MetS is strongly associated with risk for developing future diabetes and atherosclerotic and
nonatherosclerotic cardiovascular disease (CVD). Though beyond the scope of this cross-sec-
tional work, CpG sites associated with MetS may be the cause or consequence of the condition
(or features of the condition). Therefore, a MetS MRS score may capture information about
cumulative exposure to risk trait features. Importantly, this information could improve upon
existing risk algorithms (constructed from clinical, demographic and lifestyle factors) used to
predict future cardiometabolic disease. For instance, in a study set in the Bogalusa Heart Study
five well-documented diabetes risk scores (non-genomic) were tested, and all showed signifi-
cant associations with development of incident diabetes. These five unique risk scores differed
slightly by make-up of 5–10 traditional risk factors (e.g. hypertension, smoking, family history
of diabetes, age, and waist circumference), but, in general, showed good specificity but poor
sensitivity. Because of the low sensitivity, the authors concluded that an opportunity remains
Table 4. Cohort-specific association of the Methylation Risk Score (MRS) with MetS and MetS components.
Outcomes HyperGEN� P GOLDN�� P
MetS 2.25 (1.80–2.86) 6.36E-10 2.46 (2.03–3.0) 2.0E-16
MetS (M only) 1.67(1.21–2.33) 2.10E-3 2.16 (1.65–2.84) 2.49E-8
MetS (F only) 2.34 (1.78–3.02) 3.29E-10 2.75 (2.06–3.67) 7.53E-12
Elevated BP 1.36 (1.12–1.68) 2.52E-3 1.66 (1.35–2.04) 1.65E-6
High WC 1.81 (1.46–2.25) 6.16E-8 1.86 (1.56–2.23) 7.49E-12
Low HDL 1.24 (1.04–1.49) 0.013 1.35 (1.15–1.59) 2.50E-4
Elevated TG 2.10 (1.61–2.53) 1.54E-9 2.42 (2.00–2.94) 2.00E-16
Elevated FG 2.21 (1.80–2.73) 5.42E-14 1.81 (1.50–2.17) 2.14E-10
�HyperGEN model adjusted for age, sex, study site, 4 ancestry principle components, estimated blood cell counts (CD8T cells, CD4T cells, Natural Killer cells, B-cells,
Monocyte cells) as fixed effects, and family id as a random effect. (N = 205 M ales (M), 409 Females (F))
��GOLDN model adjusted for age, sex, study site, 4 methylation principle components, and family id as a random effect. (N = 476 Males(M), 520 Females(F))
MetS Components: elevated waist circumference/WC (� 88 cm for women and� 102 cm for men), elevated triglycerides/TG (� 150 mg/dL) or on treatment for
dyslipidemia (statin and/or fibric acid derivative), low high-density lipoprotein/HDL cholesterol (< 40 mg/dL in men and < 50 mg/dL in women) or on treatment for
dyslipidemia (statin and/or fibric acid derivative), elevated blood pressure/BP (systolic � 130 and/or diastolic� 85 mmHg) or antihypertensive drug treatment in a
patient with a history of hypertension), and elevated fasting glucose/FG (� 100 mg/dL) or drug treatment for elevated glucose.
https://doi.org/10.1371/journal.pone.0259836.t004
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to develop a new, more sensitive diabetes prediction tools for black and white young adults
[37]. The field is similar with respect to CVD risk prediction where an excess of models and
different recommendations limit algorithm use [38, 39]. Given the importance of MetS to the
cardiometabolic disease landscape, and that MRS may help refine risk metrics in diverse popu-
lations for important clinical sequelae, further evaluation of these scores should be considered
for disease prediction.
While there are limitations to basing a MRS for MetS from blood-based DNA methylation
(due to the proxy nature of blood as a surrogate tissue for organs involved in MetS) [40–42],
the utility of blood-based DNA methylation has been proven to be highly feasible and replica-
ble for population studies of glycemic, lipid, and other metabolic traits (Table 1). While we
only had access to data derived from blood in GOLDN and HyperGEN, other studies have
shown association whole blood and buffy coat are successful proxies for tissues in epigenetic
studies [43–45]. Much of the success behind the use of blood/buffy coat as a proxy for tissue
can be attributed to the development of new methods to account for things such as cell-type
heterogeneity, which we can now accurately account and control for in statistical analyses
[46]. To identify whether the MRS was capturing specific components of MetS, we also per-
formed individual association analyses between the individual components of MetS and MRS.
Our results suggest that relationship between DNA methylation biomarkers and the develop-
ment of MetS may be driven by fasting glucose and fasting triglycerides, however, those associ-
ations were not significantly stronger than associations observed with other MetS
components, suggesting relatively similar contributions from all components of MetS to the
MRS in HyperGEN and GOLDN. Differential patterns of sex and MetS were also considered
in this study. While both HyperGEN and GOLDN had higher proportions of females com-
pared to males–particularly in HyperGEN–sensitivity analyses showed that the MetS score was
fairly consistent across sex, with slightly higher associations noted in females compared to
males. However, as noted previously, the interaction analyses between MRS and sex were not
statistically significant, suggesting that the MRS is unlikely to have been impacted by sex in
this study. The cross-sectional nature of this study, and lack of gold standard definition for
MetS are potential limitations that should be considered in future MRS assessments. However,
this study strengthened by the availability of CpGs paired metabolic data in two well character-
ized populations enabling both discovery and validation.
In summary, we developed a MRS for MetS using existing EWAS data from two population
studies of different race groups. Addition of the calculated MRS variable to a basic model of
MetS further improved model fit in the study used for score validation. Given the strength of
association observed in the current study and the strong body of literature surrounding the
CpG loci contributing to the methylation risk score, future studies may further development
of this metric for evaluating risk of metabolic syndrome.
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